Paricalcitol Versus Calcitrol in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Dependent Patients
Abstract
Objective: To compare the efficacy of paricalcitol with calcitriol for treatment of secondary hyperparathyroidism in dialysis patients.Methods
This Randomized Controlled Trial (RCT) was carried out in Department of Nephrology, FMU & Allied th th Hospital, Faisalabad in six months period from 13 November 2023 to 12 May 2024. A total of 100 dialysis dependent patients having secondary hyperparathyroidism were included and divided into two groups. Patients in Group A received paricalcitol at a dose of 1µg/day for a period of 12 weeks. Patients in Group B took calcitriol at a dosage of 0.5 micrograms per day for a period of 12 weeks. The effectiveness was evaluated after a treatment period of twelve weeks.Results
The mean age of patients in group A was 48.48 ± 6.57 years and in group B was 48.0 ± 8.01 years. Out of these 100 patients, 52 (52.0%) were males and 48 (48.0%) were females. Efficacy in Paricalcitol was seen in 41 (82.0%) patients and in Calcitriol was seen in 29 (58.0%) patients with p-value of 0088 which is statistically significant.Conclusion
This study concluded that paricalcitol is better than calcitriol for treatment of secondary hyperparathyroidism in dialysis patients.Keywords:
Dialysis, Secondary Hyperparathyroidism, Paricalcitol.Published
2025/08/23
Issue
This work is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License 
.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution BY-NC 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com